The Global Acalabrutinib Market is projected to grow at a CAGR of 18% during the forecast period 2022-2028. Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows potent targeting efficacy and efficacy in the chronic lymphocytic leukemia (CLL) mouse […]
